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1. - ABSTRACT 
Cyclooxygenase (COX) -1 and –2 catalyze the first step in the biosynthesis of prostanoids. COX-1 is constitutively 
expressed in many tissues and seems to be involved in the house keeping function of prostanoids. COX-2, the inducible isoform, 
accounts for the elevated production of prostaglandins in response to various inflammatory stimuli, hormones and growth factors. 
COX-2 expression has been also associated with cell growth regulation, tissue remodelling and carcinogenesis. More of these 
characteristics have been elucidate through using COX selective inhibitors. Recent advances in transgenic and gene-targeting 
approaches allow a sophisticated manipulation of the mouse genome by gene addition, gene deletion or gene modifications. The 
development of COX-2 genetically altered mice has provided models to elucidate the physiological and pathophysiological roles 
of this enzyme. 
2. - INTRODUCTION 
Prostaglandins (PGs) and thromboxanes (TXs), potent bioactive lipid messengers collectively known as prostanoids, are 
implicated in many physiological processes including platelet aggregation, maintenance of the gastric mucosa integrity and 
reproduction. In addition to these physiological effects, these prostanoids are regulators of inflammation, fever and pain and play 
an important role in the pathogenesis of cancer. The biosynthesis of prostanoids occurs in three steps: (i) liberation of arachidonic 
acid (AA) from membrane phospholipids by the action of phospholipase enzymes; (ii) the formation of PG endoperoxide H2 
(PGH2) from AA mediated by a prostaglandin G/H synthase (EC 1.14.99.1), also known as cyclooxygenase (COX) and (iii) the 
conversion of PGH2 to a specific prostanoid through the action of specific prostaglandin and thromboxane synthases (figure 1) 
(1). After prostanoids exited the cells via a carried mediated process, they activate prostanoids-dependent G protein-linked 
receptors (2) and nuclear receptors of the peroxysome proliferators-activating receptor family (PPARs) (3). 
Two isoforms of cyclooxygenase, COX-1 and COX-2, are known. COX-1 is constitutively expressed in many tissues and 
seems to perform housekeeping functions; by contrast, COX-2 is undetectable in most tissues except placenta, testes, macula 
densa of the kidney and brain. Nevertheless, COX-2 is rapidly induced in response to various inflammatory stimuli, hormones 
and growth factors, and has consequently been referred to as the “inducible” isoform (4). However, genetic and pharmacological 
studies in rodents suggest that both isoforms may be important in maintaining physiological homeostasis and contribute to the 
inflammatory response and carcinogenesis. Therefore, the designations as housekeeping and/or response gene may not be entirely 
accurate (5). 
COX isoenzymes were found to be approximately 600 aminoacids in size in all species. They share 61% primary 
sequence identity and have similar kinetics properties with minimal differences. It has been suggested that low concentrations of 
AA (< 2.5 μM) are oxygenated exclusively by COX-2 in intact cells (6). It was proposed that both proteins prefer separate pools 
of arachidonic acid by using different phospholipases (7). However, recent studies demonstrated that PGs production via COX-2 
in activated cells is not controlled by specific coupling between phospholipases and COXs (8).  
The structures of COX-1 and COX-2 predict that both enzymes are located in the lumen of nuclear envelope and the 
endoplasmic reticulum. However, several authors have revealed other localizations of COX-1 (lipid bodies) and COX-2 
(caveolin-1-containing vesicles). The physiological significance of the extraluminal localizations is current unknown (9). 
The COX-1 promoter region lacks a canonical TATA or CAAT box and is GC rich, features consistent with those of a 
housekeeping gene. Despite this, COX-1 is inducible in some cells like in endothelia in response to different stimuli (10, 11). On 
the other hand, there are many consensus cis-elements in the 5’ flanking region regulating the transcription of COX-2 gene, 
including a TATA box. Among them, CRE, NF-IL6 motifs, NF-kappaB site and the E-box are known to be involved in the 
regulation of COX-2 gene expression (4). Recently, several authors have shown the importance of NFAT and AP-1 sites in the 
induction of COX-2 expression upon several stimuli, including phorbol ester PMA/calcium ionophore treatment in tumoral cells 
(12), vascular endothelial growth factor in vascular endothelial cells (13) or endothelin-1 in rat glomerular mesangial cells (14). 
The cyclooxygenases are the pharmacological targets of non-steroidal anti-inflammatory drugs (NSAIDs). Ever since in 
1971 Vane first reported the mechanism of action for aspirin-like drugs (15), NSAIDs with varying of isoform specificity have 
been developed (9). Much our current understanding about the physiological roles of COX-2 has been obtained from studies with 
NSAIDs. However, it has been identified non-COX-2 targets of NSAID action, reason why the effects observed with these agents 
may not always reveal the physiological roles of COX isoforms (16-18). To better characterize the physiological and pathological 
functions of COXs, a number of genetically engineered mouse models have been generated. This review will be focused in the 
contribution of the transgenic animal models to the study the roles of COX-2 in normal and diseased states. 
Both the “gain of function” (transgenesis) and “loss of function” (gene targeting) of individual genes have been utilized 
for stable modification of the mouse genome, providing powerful experimental systems to study pathophysiology. Transgenesis 
is mainly achieved by microinjection of the transgenic construct into the pronucleus of 1-cell embryos, which are subsequently 
implanted into pseudopregnant female mice. In the gene-targeting approach, a gene of interest is replaced with a mutated 
sequence in embryonic stem cells via homologous recombination. The targeted ES cells are microinjected into blastocysts that 
are then implanted into receiving females (figure 2) (19).  
In spite of the modest number of animal models that constitutively express COX-2, the transgenic mice have provided 
valuable insight into the COX-2 contribution to tumorigenesis (20-23).  
COX knockout models have been profoundly studied. All COX-deficient mice, including the double COX-1/COX-2 
knockout mice, are produced in the expected Mendelian ratio, indicating that in mice, embryo implantation and survival in utero 
does not require fetal PG synthesis (24-27). COX-2 knockout animals lacked the respective normal size message and protein and 
nor did appear to upregulate the expression of COX-1. Mice deficient in both isoforms are born alive but they die during the first 
day of life because the ductus arteriosus fails to close after birth. For COX-2-deficent mice that are either wild-type or 
heterozygous for the COX-1 gene, neonatal mortality is 35 or 79%, respectively. These findings indicate that the PG synthesis 
required for normal closure of the ductus arteriosus depends primarily on COX-2, although COX-1 provides partial compensation 
in mice deficient in COX-2.  
3. INSIGHT INTO THE PHYSIOLOGICAL ROLES OF COX-2 THROUGH GENETICALLY ALTERED MICE 
3.1 Kidney 
The kidney is a tissue rich in PG synthesis. Several studies have looked at the importance of COX-2 in renal 
pathophysiology. In a rat model of glomerulonephritis involving mesangiolysis, the selective inhibition of COX-2 impaired 
glomerular capillary repair (28). In patients with active lupus nephritis, both renal and systemic COX-2 was upregulated (29). In 
other models of renal injury such as the remnant kidney, renovascular hypertension and diabetes, increased COX-2 renal 
expression has also been detected [see (30) for review]. But, it has only been possible to identify a prominent role for COX-2 in 
both the development and function of the kidney through the characterization of COX-2 knockout model. 
One of the most striking findings in the mice lacking the COX-2 gene was the conspicuous abnormalities in kidney 
structure, mainly consisting of nephron hypoplasia and tubular atrophy. The renal pathology became more severe with age, 
resulting in end-stage renal disease (25, 26). In the neonatal mouse kidney, the expression of COX-2 increases during the first 4 
days after birth and thereafter declines to undetectable levels (31). The initial defects in kidney development in COX-2-null mice 
are observed at 10 days after birth, with the cortex being abnormally thin with regions of small immature glomeruli and tubular 
atrophy. In adult COX-2 -/- mice, the nephropathy steps forward tubular dilation, interstitial fibrosis and glomerular sclerosis 
(32). However, it may possible to overcome this developmental defect by cross-breeding the original COX-2 C57BL/6 deficient 
mice with a DBA/1 strain (33). The DBA/B6 mice live a full life span with a normal kidney development (34). Recently, Yang et 
al have studied whether the severity of renal failure in COX-2 deficient mice is also affected by genetic background. Only the 
male 129/COX-2 deficient mice showed abundant protein casts, dilated tubules and infiltration of inflammatory cells. However, 
the presence of small glomeruli in the nephrogenic zone was observed in all studied strains regardless of genetic background and 
gender. Therefore, the severity of renal failure in COX-2 null mice is influenced by genetic background whereas the incomplete 
maturation of outer cortical nephrons appears to be independent of genetic background effects (35). 
In addition to its role in postnatal renal development, COX-2 also contributes to modulate specific functions in adult 
kidney. In the renal cortex, COX-2 expression is localized to the macula densa and the adjacent thick ascending limb, in where 
COX-2 expression is induced by reductions in the NaCl concentrations (36). Thanks to COX-2 deficient mice, it has been 
proposed a role of COX-2 in the stimulation of renin production and secretion following reduced dietary sodium (37) or the 
inhibition of angiotensin-converting enzyme (38). Under conditions where renin expression and activity are induced in wild-type 
mice, the kidneys from COX-2 deficient mice do not respond to these stimuli. Therefore, COX-2 appears to be the isoform 
primarily responsible for maintaining renal homeostatic functions involved in the regulation of salt resorption, fluid volume and 
blood pressure. 
3.2 Gastrointestinal Tract 
PG synthesis can be demonstrated to occur in every part of the gastrointestinal tract where they have a cytoprotective 
role. In rat tissues, the PGs levels were greatest in gastric muscle and forestomach, followed by gastric mucosa, colon, rectum, 
ileum, cecum, duodenum, jejunum and esophagus. The mechanism of the cytoprotective action of PGs is complex and involves 
the decrease of secretion of gastric acid, the direct vasodilator action on the gastric mucose and the stimulation of viscous mucus 
(9). 
Initially, it has been proposed that PG synthesis dependent on COX-1 is important for maintenance of mucosal integrity. 
Thus, the inhibition of COX-1 was thought responsible for ulcerative effects of NSAIDs. The reduced gastric toxicity of COX-2 
selective inhibition further supported this hypothesis (39). However, the COX-1 deficient mice did not spontaneously develop 
stomach ulcers (24). Moreover, COX-2 null mice were more susceptible to colonic injury with dextran sodium sulfate than wild-
type mice (40). Similarly, SC-560, a selective COX-1 inhibitor, or celecoxib, a selective COX-2 inhibitor, administrated to rats, 
produced gastric damage. Thus, genetic and pharmacological studies in rodents suggest that the combined inhibition of both 
COX-1 and COX-2 is required to produce gastric damage  
3.3 Reproduction 
Whereas COX-2 null male mice showed normal fertility, the deletion of the COX-2 gene in female mice resulted in 
infertility with defects in ovulation, implantation and decidualization. Lim et al (41) observed that few eggs were recovered 
following superovulation of COX-2 null mice, and only 2% of the released eggs were fertilized. In preovulatory follicles, COX-2 
expression is normally induced by pituitary gonadotropins, indicating that COX-2 accounted for increased ovarian PG production 
following the luteinizing hormone surge (42). The decrease of PGE2 synthesis in the ovaries of COX-2 knockout mice disrupts 
cumulus activation, stigmata formation and ovulation, which can be restored by treatment with PGE2 (42). The process of 
ovulation becomes extremely poor in COX-2 or EP2-null mice, suggesting an important role of COX-2-derived PGE2 in this 
process. Moreover, ovulation in younger COX-2 knock out mice that responded to gonadotropins for superovulation, was 
superior compared to that in adult COX-2 deficient mice, suggesting that ovulatory process becomes more dependent on COX-2-
derived PGE2 effects with aging (43). However, follicular growth in vivo and oocyte maturation in vivo or in vitro are, 
apparently, normal in both knock out models. Furthermore, subsequent in vitro fertilization of oocytes and their development in 
vitro proceed normally to blastocyst stage. In addition, many of these blastocysts showed signs of zona hatching, suggesting that 
COX-2-derived PGE2 of maternal origin is not required for oocyte maturation, fertilization or preimplantation development (43).  
COX-2 and PGI synthase (PGIS) coexist at the implantation site, suggesting the availability of PGI2 directly to uterine 
cells. Concerning a target receptor for PGI2 in the uterus, PPARδ was shown highly colocalized at similar regions of the 
implantation sites with COX-2 and PGIS; the expression of other known receptors activated by PGI2, IP and PPARα, was very 
low to undetectable. The functionality of PPARδ as a PGI2 receptor was further validated in vivo, using COX-2-deficient mice as 
a model. Administration of cPGI (carbaprostacyclin, PGI2 agonist) or L-165041 (a selective PPARδ agonist) improved 
implantation and decidualization defects in COX-2(-/-) mice. This effect is further potentiated by RXR agonists (44). 
Interestingly, coadministration of cPGI with PGE2 markedly improved embryonic and decidual growth in COX-2 deficient mice 
(44).  
In conclusion, the study of COX-2 deficient mice has established the essential role of COX-2 in female reproductive 
process. The fact that COX-2-derived PGE2 participates in ovulation and fertilization via the EP2 receptor subtype (45), whereas 
COX-2-derived PGI2 is important for the initial stages of implantation and subsequent decidualization, via the nuclear receptor 
PPARδ in the uterus, illustrate a fascinating distinction as to how specific PGs elicit unique physiological function through 
utilization of differential signaling pathways. 
3.4 Brain 
Brain (neurons of hippocampus, cerebral cortex, amygdale and hypothalamus) and spinal cord express relatively high 
basal levels of COX-2, which is though to play a role in fundamental brain functions, such as synaptic activity, synaptic 
remodeling, memory consolidation and functional hyperemia (46, 47). COX-2 expression is rapidly and transiently upregulated 
in neurons microglia and astrocytes in response to excitatory synaptic transmission mediated by NMDA receptor activation (46) 
or a variety of neurotoxic stimuli (48-50).  
COX-2 deficient mice show increased resistance to focal ischemic injury induced by transient middle cerebral artery 
occlusion or by NMDA-induced neurotoxicity (51). The lower degree of hippocampal neuronal injury in COX-2 deficient mice 
agreed with an attenuation of DNA fragmentation in the hippocampus, event reproduced by nimesulide treatment (52). The 
inhibition of COX-2 protein expression protected the dopaminergic neurons in substantia nigra pars compacta, suggesting a 
potential therapeutic implication (53). These results show that neuronal COX-2 is likely to function in promoting neuronal injury. 
The injury conditions indicated above involve an activation of the NF-kappaB pathway. Rao et al (54) have recently 
showed that NF-kappaB DNA binding activity was significantly decreased in COX-2 null mice compared to wild-type mice, 
possibly due to a decrease in brain protein levels of p65, phosphorylated-p65 and phosphorylated-Ikappa-B alpha levels. These 
results suggest a reciprocal coupling between NF-kappaB and COX-2. 
It has also been developed a C57BL6/J inbred strain transgenic mouse model in which human COX-2 was selectively 
overexpressed in neurons of the central nervous system using the Thy-1 promoter (HCOX-2 mice). This promoter has a high 
level of neuron-specific expression that begins in the second postnatal week (55). HCOX-2 mice develop cognitive deficits in an 
age-dependent manner, associated with a parallel age-dependent increase in neuronal apoptosis and astrocytic activation (22). 
HCOX-2 mice have been also tested in a model of transient focal ischemia. A significant increase in infarct volume was observed 
after middle cerebral artery occlusion, supporting previous mentioned studies in COX-2 null mice (56). 
3.5 Cardiovascular System 
COX-1 is highly expressed in the normal vascular tissues, whereas COX-2 expression is elevated in proliferating vascular 
cells, for example angiogenic microvessels, atherosclerotic lesions and inflamed tissues (57). It has also been reported the 
expression of COX-2 in ischemic human myocardium and in dilated cardiomyopathy, but not in normal cardiomyocytes (58). All 
these findings seem indicate a detrimental role of COX-2 in cardiovascular homeostasis. 
However, there are also evidences suggesting physiologically important protective actions of COX-2. In contrast of 
Wong’s work, 50% of COX-2 null mice developed a diffuse myocardial fibrosis, suggesting that COX-2 deficiency might be 
involved in cardiomyopathy (26). COX-2 protects cardiomyocytes against oxidative stress (59) and the increase in COX-2 
activity associated to ischemic preconditioning mediates the protective effects of the late phase of preconditioning against both 
myocardial stunning and myocardial infarction (60). Furthermore, pharmacological COX-2 inhibition improved cardiac function 
after myocardial infarction in the mouse (61).  
In addition, the clinical experience accumulated with COX-2 inhibitors in the past three years also suggests the protective 
effects of COX-2 in patients with cardiovascular disease (62). Thus, the Vioxx Gastrointestinal Outcomes Research clinical trial 
showed a fivefold increase in myocardial infarction in patients treated with rofecoxib compared with the traditional NSAID 
naproxen (63). The COX-2 inhibitors reduce the production of prostacyclin (PGI2) but not that of COX-1-derived thromboxane 
A2 (TXA2). Thus, the effects of TXA2 are exacerbated during extended therapy with specific COX-2 inhibitors (COXIBs), 
potentially predisposing patients to heart attack and stroke (64, 65). 
At sight of all these data, we can conclude that the actions of prostanoids in pathological situations are varied and 
complex. Some appear to be beneficial, countering the worst effects of disease, whereas others contribute to its further 
development. This complexity might derive from the fact that different cell types in the heart, e.g., myocytes, fibroblasts and 
endothelial cells produce different prostanoids profiles. The effect of COX-2 induction or inhibition will depend on the cell in 
which it is expressed, the prostanoids produced, and the ability of surrounding cells to respond to these prostanoids. The outcome 
of COX-2 activity and subsequent prostanoid signaling will therefore be an exquisite and highly dynamic balance among these 
different and often conflicting signals. Disturbance of this delicate balance may determine whether prostanoid signals have 
beneficial or deleterious effects during the development of important cardiovascular pathologies; a comprehensive understanding 
of prostanoid actions and functions during these disease processes are required. In that sense, in our group we have generated a 
transgenic mouse that constitutively expresses COX-2 in cardiomyocytes. With this model we try to know with better precision 
the pathophysiologic role of COX-2 in the heart. 
3.6 Liver 
There are many studies that reported COX-2 expression and induction in whole liver homogenates, mainly in different 
experimental models of liver pathology (66, 67). The expression and induction of COX-2 in Kupffer cells is well documented. 
COX-2 expression in these cells was increased by different stimuli such as hyperosmolarity (68), alcohol (66), proinflammatory 
cytokines and LPS (69, 70) both in vitro and in vivo. However, the contribution of hepatocytes to liver PGs synthesis is more 
controversial. Johston et al (71) using ricin-purified hepatocytes to completely eliminate Kupffer and endothelial cells, 
demonstrated that hepatocytes do not produce COX products even with conditions favoring lipid peroxidation. 
Hepatocytes respond to most of the stimuli that positively regulate COX-2 expression in other cells, including LPS, IL-1 
beta and TNF-alpha. Interestingly, fetal hepatocytes, which exhibit a liver phenotype distinct from the adult counterpart, were 
able to express COX-2 upon challenge with LPS and pro-inflammatory cytokines (72). Regarding the mechanism responsible for 
the suppression of COX-2 inducibility in adult hepatocytes, our results have shown that the activity of the COX-2 promoter 
declined rapidly after birth paralleling the expression of C/EBP-alpha in neonatal hepatocytes (73). Attractively, partial 
hepatectomy (PH) favors hepatocyte de-differentiation and triggers a rapid regenerative response in the remnant tissue to 
reinstate the organ function and the cell number. In this vein, it has been shown that COX-2 is expressed in liver at 16 hours after 
PH (74). Studies of PH through animal models have recently been reviewed in greater detail elsewhere (75). 
Studies in the physiological significance of COX-2 expression after PH showed alterations in various parameters of cell 
cycle progression in animals pretreated with NS398, a selective COX-2 inhibitor, and in COX-2 deficient mice (74, 76). In the 
genetic model of COX-2 targeting in mice, our own data demonstrated that the lack of PG synthesis results in a delay in the first 
cycle of hepatocyte proliferation. However, measurement of overall liver mass recovery one week after PH failed to show 
significant differences between control and COX-2 deficient animals, which suggest that other growth-promoting mechanisms 
play a more significant role in the latter phase of the regeneration process (figure 3). 
In conclusion, most of the results indicate that COX-2 expression in hepatocytes is restricted to those situations in which 
dedifferentiation or proliferation occurs, suggesting an important role of PGs in the onset of liver pathologies including 
hepatocellular carcinoma (HCC) (77).  
4. COX-2 IN PATHOLOGICAL STATES 
4.1 Inflammation 
The initial studies for characterizing the COX-2 contribution to the development of inflammation involved the induction 
of edema by 12-o-tetradecanoylphorbol-13-cetate (TPA), a potent inducer of COX-2 expression, applied topically to the ear of 
COX-2 knockout mice (78). Surprisingly, the level of edema induced by TPA was not significantly different between wild-type 
and COX-2 deficient mice.  
Sepsis is a systemic inflammatory response to a blood-borne infection that is associated with an extremely high rate of 
morbidity and mortality. COX-2 deficient mice are resistant to many of the detrimental consequences of endotoxemia such as the 
leukocyte infiltration into critical organs (kidneys and lung), the induction of nitric oxide synthase 2 and heme oxygenase-1 or 
activation of NF-kappaB pathway (79). These beneficial effects occur in part by a compensatory increase in IL-10 that 
counterbalances the pro-inflammatory host response to endotoxemia. Thus, COX-2 is a critical component of the lethal response 
associated with endotoxemia in mice. 
Comparing the results observed in endotoxemic COX-2 null mice or mice treated with TPA, it has been deduced that the 
importance of COX-2 in an inflammatory response may also depend on the initiating stimulus. 
4.2 Tumorigenesis 
The role of COX-2 and the PGs resulting from its enzymatic activity in modulating cell growth and the development of 
neoplasia is well established mainly in colon cancer (80). Overexpression of COX-2 promotes tumorigenesis in colon cells and in 
some models of transgenic mice, whereas inhibition of COX-2 by NSAIDs and COXIBs is anti-neoplasic although COX 
independent pathways could also be involved in the antiproliferative effects of NSAIDs (81, 82). In fact, al least five mechanisms 
by which COX-2 contributes to tumorigenesis and malignant phenotype have been proposed: inhibition of apoptosis mediated by 
Bcl-2, Par-4 and protein kinase B (Akt/PKB) signalling (83, 84), increased angiogenesis through the production of VEGF and 
PGs (85) increased invasiveness via activation of metalloproteinases (86) and conversion of procarcinogens to carcinogens (87). 
Is COX-2 overexpression sufficient to induce tumorigenesis? Several COX-2 genetically altered mice models have been 
developed for answering this question. 
4.2.1. Gastric and Intestinal Tumors 
In 1996 Oshima and collaborators provided definitive evidence that COX-2 is required for intestinal tumorigenesis. In a 
mouse model of human familial adenomatous polyposis, intestinal tumor development is reduced by the genetic deficiency of 
COX-2 (88). However, by utilizing COX-1 deficient mice, Lagenbach et al showed that deletion of COX-1 gene also attenuated 
polyp formation (89). Therefore, both COX-1 and COX-2 may be important in intestinal tumorigenesis. 
Accumulating evidence shows that COX-2 expression is also induced in the gastric cancer tissues (90). Among various 
prostanoids, PGE2 appears to be the responsible for cancer development (91). To investigate the role of COX-2 in gastric 
tumorigenesis, transgenic mice simultaneously expressing COX-2 and microsomal PGE2 synthase was generated. The specific 
gastric epithelial cell expression was obtained by using the cytokeratin 19 (K19) promoter (92). The transgenic mice developed 
metaplasia, hyperplasia and tumors in the glandular stomach with heavy macrophage infiltrations (20). 
4.2.2. Breast Cancer 
The question of whether COX-2 overepression is sufficient to induce tumorigenesis was addressed by human COX-2 
overexpression in the mammary glands of CD1 mice using the mouse mammary tumor virus promoter (MMTV). This promoter 
is highly expressed in the mammary epithelium during pregnancy and lactation (93). Female virgin COX-2 transgenic mice 
showed precocious alveolar differentiation and enhanced expression of beta casein gene. Multiparous females exhibited 
exaggerated incidence of focal mammary gland hyperplasia, dysplasia, and transformation into metastatic tumors. The reduced 
levels of Bax and Bcl-XL proteins and the decrease of Bcl-2 levels in COX-2 induced tumors suggested that decreased apoptosis 
of mammary epithelial cells contribute to tumorigenesis (21). Moreover, PGE2 stimulated the expression of angiogenic regulatory 
genes in mammary tumor cells isolated from MMTV-COX-2 transgenic mice (94). These results define, in part, the molecular 
basis of how COX-2 transforms the mammary gland into a tumorigenic state. Recently, it has been showed that PGE2 stimulates 
angiogenesis via the EP2 receptor, mediating VEGF upregulation via the cAMP/PKA pathway (95). 
 Narko and collaborators have been characterized the MMTV-COX-2 FVB/N transgenic mice (96). FVB/N is an inbred 
strain which has robust reproductive characteristics and is susceptible to breast cancer formation. MMTV-COX-2 FVB/N 
transgenic mice had high incidence of mammary tumors similar to CD1 mice suggesting that observed phenotype is due to COX-
2 expression and not an aberrant effect of site of integration. 
4.2.3. Skin Carcinogenesis 
Recent transgenic overexpression studies in which COX-2 was targeted to the skin of transgenic mice support the notion 
that upregulated expression of COX-2, perhaps induced by carcinogenic stimuli or other tumor promoters, is an important 
contributor of tumorigenesis. In mice and humans, deregulated expression of COX-2, but not of COX-1, is characteristic of 
epithelial tumors, including squamous cell carcinomas of skin (97). To explore the function of COX-2 in epidermis, a keratin 5 
promoter was used to direct COX-2 expression to basal epidermal cells and the pilosebaceous unit of mouse skin (K5-COX-2) 
(23). The transgenic animals did not exhibit symptoms of inflammation, indicating that COX-2 expression alone is not sufficient 
to initiate an inflammatory response in mouse skin. 
K5-COX-2 mice morphogenesis of pelage and the number of hair follicles was reduced probably due to an impairment of 
hair follicle induction. Furthermore, transgenic mice developed alopecia (98). Aberrant COX-2 expression in basal gland 
epithelial cells correlated with sebaceous gland hyperplasia and increase of epicutaneous sebum levels (23). The K5-COX-2 
transgenic mice did not develop skin tumors spontaneously but did so after a single application of an initiating dose of the 
carcinogen 7, 12-dimethyl-benz[a]anthracene (DMBA) (99). Thus, overexpression of COX-2 targeted to basal keratinocytes 
contributes to skin-tumor promotion and progression by establishing a preneoplasic skin phenotype. Nevertheless, these results 
are in controversy with other authors who have shown that the COX-2 deficiency altered epidermal differentiation and reduced 
mouse skin tumorigenesis (100). 
COX-2 null mice have been also used to evaluate the involvement of COX-2 activity in sulfur mustard induced skin 
toxicity (101). Sulfur mustard (SM) is a potent vesicant and chemical warfare agent that induces tissue damage involving an 
inflammatory response (102). The relatively low susceptibility of COX-2 null mice to SM, expressed by reduced ear swelling and 
absence of epidermal ulceration and encrustation, demonstrates that COX-2 actively participates in the acute phase of 
inflammation caused by SM. 
4.2.4. Hepatocellular Carcinoma 
Although the pathogenesis of hepatocellular carcinoma (HCC) remains poorly defined, several studies indicate that this is 
a multifactorial, multistep process involving the alteration of oncogenes, tumor suppressor genes and host chromosomes, as well 
as an abnormal expression of growth factors and COX-2 on the whole resulting in a reduced apoptosis. 
COX-2 expression in human hepatoma cell lines is well documented. COX-2 is expressed in 75% of different hepatoma 
cell lines studied, for example, HepG2, HuH7, Hep3B, Sk-hep 1 and SMMC-7721 cells (103-107). Failure of apoptosis is an 
important event in tumor progression and resistance to cytotoxic therapy (108). Treatment of these cells with COX-2 inhibitors, 
such as aspirin, nimesulide, NS-398 or celecoxib, inhibited cell growth, invasiveness and proliferation at the time that induced 
apoptosis. With respect to the mechanisms involved, it has been proposed that COX-2 promotes hepatocellular carcinoma 
progression through Akt activation (109). Aspirin and NS-398 inhibit HGF-induced invasiveness in HepG2 cells through 
ERK1/2 activation (106) and apoptosis induced by COX-2 inhibitors was correlated with the activation of caspase-9, 3 and 6 
(103).  
However, the in vitro anti-HCC effect of NSAIDs and COXIBs needs to be confirmed in animal models in vivo. In this sense, we 
have developed, as an initial approach, an in vivo model to deliver the human COX-2 gene to the mouse liver via hydrodynamics-
based transient transfection as described previously (110). Through this model, it has been demonstrated that PGs produced by 
COX-2 expression protected the liver against Fas-mediated apoptosis. The mechanism involves potent inhibition of caspases 3 
and 9 (unpublished data). Moreover, our group is working to develop a transgenic mice model that constitutively express COX-2 
in hepatocytes to confirm the involvement of COX-2 in HCC and the anti-tumoral effects of the COX-2 inhibitors. 
5. SUMMARY AND PERSPECTIVES 
Generation and characterization of COX-2 genetically altered mouse models, as reviewed in this article, have greatly 
facilitated identification of the mechanisms by which the COX-2 contributed to normal physiology and various pathological 
states (table 1). However, caution should be exercised when we used this powerful technology because, for example, differences 
in genetic background of different mouse strains can affect transgene expression and phenotype due to strain specific modifiers 
of expression.  
Nevertheless, future refinement and generation of new COX-transgenic models, including the generation of conditional 
gene-targeted mouse models that may allow for the temporal and spatial control of gene expression, would be a tremendous 
advantage in exploring the genetic basis of COX-2 function and dysfunction. Furthermore, it can be anticipated that new 
approaches will appear which permit control not only the COX-2 activity, spatially and temporally, but also quantitatively, which 
is known to be central to many biological process. 
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 FIGURE LEGENDS 
Figure 1. The arachidonic acid cascade: role of the cyclooxygenase in the production of the constitutive and inducible 
eicosanoids (prostaglandins, thromboxanes and leukotrienes). The primary function of each eicosanoid is shown. 
 
 
Figure 2. Schematic diagrams of transgenic (panel A) or gene-targeting (panel B) approaches for stable modification of the 
mouse genome. 
 
 
 
x 
vasectomized 
birth
superovulated 
x
fertile 
Collection of the 
 fertilized eggs 
Micro-injection 
Reimplantation 
pseudopregnant 
A 
X 
129  agouti  
Embryonic stem cells (ES) 
Trophoblast 
blastocyst (3,5 jpc) 
Inactivation 
construction 
Selection  
genotyping  
of the resistants 
clones (RH) 
X 
C57Bl 
Host embryo 
microinjection  Uterine 
Reimplantation 
Chimeric mice  
B 
Figure 3. Physiological significance of COX-2 expression after PH showed alterations in various parameters of cell cycle 
progression: COX-2 deficient mice (KO) mice exhibited an impaired incorporation of [3H]thymidine into hepatocyte nuclei at 
48h after PH (radioactive nuclei appear yellow) and, in agreement with these results, the levels of PCNA, a marker of S phase, 
were 65% lower in the KO mice compared with the wild-type littermates. 
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Table 1. Characteristics of COX-2 genetically altered mouse. 
Pathophysiological Process Transgenic mice COX-2 deficient mice 
Neonatal mortality  Increased (25,26,27) 
Adult mortality  Increased (25) 
Patent ductus arteriosus  Increased (27) 
Postnatal kidney development  Impaired (25,26,32) 
Renal homeostasis functions  Altered (36,37,38) 
Ovulation/Implantation/Decidualization  Impaired (41,42) 
Mucosal integrity  Normal (24) 
Neuronal injury Increased (22) Increased (51,52,53) 
Cognitive deficits Age-dependent (56)  
Cardiac fibrosis  Increased (26) 
Liver regeneration  Altered (74) 
Inflammation  Altered (79) 
Intestinal tumorigenesis Increased (20) Decreased (88) 
Mammary gland Metastatic tumors (21,96)  
Morphogenesis and number of hair 
follicles 
Altered (alopecia) (98)  
Sebaceous glands Hyperplasia (23)  
Skin tumors 
Increased in response of carcinogens 
(99) 
Reduced (101,102) 
Liver apoptosis  Protected (unpublished data) 
 
 
 
 
 
